Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.
Justa Friebus-KardashAnja GäcklerAndreas KribbenOliver WitzkeHeiner WedemeyerJürgen TreckmannKerstin HerzerUte EisenbergerPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2019)
Early administration of a sofosbuvir-based regimen to HCV-negative recipients of kidneys from HCV-viremic donors is feasible and safe. The definition of an optimal therapeutic approach warrants further investigation.